View Future GrowthLavipharm 과거 순이익 실적과거 기준 점검 2/6Lavipharm은 연평균 29.5%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.4% 증가했습니다. 매출은 연평균 9.6%의 비율로 증가했습니다. Lavipharm의 자기자본이익률은 9.2%이고 순이익률은 8%입니다.핵심 정보29.48%순이익 성장률-35.63%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률12.39%매출 성장률9.56%자기자본이익률9.18%순이익률8.02%다음 순이익 업데이트17 Sep 2026최근 과거 실적 업데이트Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...모든 업데이트 보기Recent updatesDeclared Dividend • Jun 28Dividend of €0.02 announcedDividend of €0.02 is the same as last year. Ex-date: 20th July 2026 Payment date: 24th July 2026 Dividend yield will be 1.3%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (172% earnings payout ratio) nor is it covered by cash flows (167% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 92% to bring the payout ratio under control. However, EPS has declined by 26% over the last 5 years so the company would need to reverse this trend.공시 • Jun 27Lavipharm S.A. announces Annual dividend, payable on July 24, 2026Lavipharm S.A. announced Annual dividend of EUR 0.0200 per share payable on July 24, 2026, ex-date on July 20, 2026 and record date on July 21, 2026.New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026분석 기사 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).분석 기사 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024분석 기사 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024분석 기사 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023분석 기사 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.공시 • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.공시 • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.분석 기사 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year.매출 및 비용 세부 내역Lavipharm가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ATSE:LAVI 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 2665523031 Dec 2563523030 Sep 2555221130 Jun 2555221131 Mar 2552921131 Dec 2453921130 Sep 2446918030 Jun 2447819031 Mar 2452219031 Dec 2348218030 Sep 2354016130 Jun 2344116131 Mar 2349116131 Dec 2239115130 Sep 224324030 Jun 2241115131 Mar 2241112131 Dec 2140215130 Sep 2139215130 Jun 2139314131 Mar 2138214131 Dec 2038214130 Sep 2037414130 Jun 2036714131 Mar 2035614131 Dec 1934514130 Sep 1934314130 Jun 1934114131 Mar 1934115131 Dec 1834115130 Sep 1833016130 Jun 1832-116131 Mar 1832616131 Dec 17321315230 Sep 17321117230 Jun 17321018231 Mar 1732718231 Dec 1631418330 Sep 1631418330 Jun 1628415331 Mar 1627-215331 Dec 1526-715330 Sep 1527-9154양질의 수익: LAVI는 고품질 수익을 보유하고 있습니다.이익 마진 증가: LAVI의 현재 순 이익률 (8%)은 지난해 (16.3%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: LAVI의 수익은 지난 5년 동안 연평균 29.5%로 크게 증가했습니다.성장 가속화: LAVI은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: LAVI은 지난 1년 동안 수익이 감소(-39.7%)하여 Pharmaceuticals 업계 평균(15.1%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: LAVI의 자본 수익률(9.2%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/01 19:46종가2026/07/01 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lavipharm S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Declared Dividend • Jun 28Dividend of €0.02 announcedDividend of €0.02 is the same as last year. Ex-date: 20th July 2026 Payment date: 24th July 2026 Dividend yield will be 1.3%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (172% earnings payout ratio) nor is it covered by cash flows (167% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 92% to bring the payout ratio under control. However, EPS has declined by 26% over the last 5 years so the company would need to reverse this trend.
공시 • Jun 27Lavipharm S.A. announces Annual dividend, payable on July 24, 2026Lavipharm S.A. announced Annual dividend of EUR 0.0200 per share payable on July 24, 2026, ex-date on July 20, 2026 and record date on July 21, 2026.
New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.
Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
분석 기사 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...
New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).
분석 기사 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).
Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.
분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).
공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
분석 기사 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...
Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
분석 기사 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...
New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.
공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
분석 기사 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
공시 • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.
공시 • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.
Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.
Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
분석 기사 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...
Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year.